Analyst says Fuzeon's side effects will limit its use
September 09 2004 11:00 PM ET
Because the injectable anti-HIV drug Fuzeon can cause small knots on the skin where it is injected--and severe skin reactions in 10% to 15% of the people who take it--the drug's use will likely be limited to just two to three years because patients will "eventually run out of skin surface for injection," according to an new analyst report, The News and Observer of Raleigh, N.C., reports. Thomas Wei, an analyst at Piper Jaffray, suggests that Fuzeon will likely never become a huge commercial success because of the skin reactions associated with its twice-daily injections. Other studies have suggested Fuzeon's price tag--about $20,000 per year--also are restricting its use.
But not all analysts agree with Wei's report. Sharon Seiler, an analyst at Punk, Ziegel, and Co., says adverse side effects are likely not going to be enough to prevent HIV patients who've exhausted all other treatment options from using Fuzeon. Officials at pharmaceutical company Trimeris, which markets Fuzeon jointly with Roche, note that the discontinuation rate among Fuzeon users is similar to that of other anti-HIV medications. Trimeris also reports that it is working on a new formulation of Fuzeon that could reduce the number of injections required in order to minimize skin reactions.
- World News German President Will Boycott Sochi Olympics December 08 2013 3:16 PM
- Marriage Equality Gay Teacher Fired After Obtaining Marriage License December 08 2013 2:31 PM
- Comedy WATCH: Ellen and Portia Recreate Bound 2 December 08 2013 2:15 PM
- Music A Brief History of Macklemore's 'Same Love' December 08 2013 9:10 AM
- Transgender Gay, Trans Identities Don't Exist, Says Colo. School Board Member December 08 2013 7:00 AM
- World News PHOTOS: Don't Miss the Message in Rome's Beautiful New Lights December 08 2013 1:47 AM
- Travel Wedding Bells Ring Down Under December 07 2013 3:33 PM